Download PDF
Thromb Haemost 1982; 48(01): 018-020
DOI: 10.1055/s-0038-1657206
Original Article
Schattauer GmbH Stuttgart

Platelet Sensitivity to Prostacyclin and Thromboxane Production in Hyperlipidemic Patients

A Strano
The Institute of Clinical Medicine I, Italy
,
G Davì
The Institute of Clinical Medicine I, Italy
,
M Averna
The Institute of Clinical Medicine I, Italy
,
G B Rini
The Institute of Clinical Medicine I, Italy
,
S Novo
The Institute of Clinical Medicine I, Italy
,
G Di Fede
The Institute of Clinical Medicine I, Italy
,
A Mattina
The Institute of Clinical Medicine I, Italy
,
A Notarbartolo
*   Department of Gerontology, University of Palermo, Italy
› Author Affiliations
Further Information

Publication History

Received 08 February 1982

Accepted 24 May 1982

Publication Date:
13 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In 13 type II hyperlipidemics (10 males and 3 females; mean age 50.2 ± 10.6 years), in 10 type IV hyperlipidemics (7 males and 3 females; mean age 51 ± 13.3 years) and in 23 healthy age-and sex-matched controls, the following parameters were measured: plasma cholesterol; plasma TG; plasma C-HDL; VLDL, separated in a preparative ultracentrifuge; C-LDL; Apo B, with immunoelectrophoretic method; platelet sensitivity to prostacyclin; TXB2 formation in PRP; TXB2 in serum.

This study provides evidence for: 1. Reduced platelet sensitivity to prostacyclin, more evident in type II hyperlipidemia that provides an additional mechanism involved in increased platelet aggregation found in type II hyperlipidemia.

2. Enhanced TXB2 formation in PRP after thrombin stimulation (664.65 ± 142.18 pmol/108 platelets) only in type II hyperlipidemics and such enhanced formation was positively correlated to C-LDL (r = 0.53; p <0.05) and to Apo B (r = 0.62; p <0.05); serum TXB2 formation rate was also increased in type II hyperlipidemia.

Keywords

Hyperlipidemia - Thromboxane - Platelet sensitivity to prostacyclin
 

  • References

  • 1 Bizios R, Wong LK, Vaillancourt R, Lees RS, Carvalho AC. Platelet prostaglandin endoperoxides formation in hyperlipidemias. Thromb Haemostas 1977; 38: 228 (Abstr.)
    PubMedGoogle Scholar
  • 2 Tremoli E, Folco G, Agradi E, Galli C. Platelet thromboxanes and serum cholesterol. Lancet 1979; 1: 107-108
    PubMedGoogle Scholar
  • 3 Stuart MJ, Gerrard JM, White JG. Effect of cholesterol on production of thromboxane B2 by platelets in vitro. N Engl J Med 1980; 302: 6-10
    CrossrefPubMedGoogle Scholar
  • 4 Shattil SJ, Bennet JS, Colman RW, Cooper RA. Abnormalities of cholesterol phospholipid composition in platelets and low-density lipoproteins of human hyperbetalipoproteinemia. J Lab Clin Med 1977; 89: 341-353
    PubMedGoogle Scholar
  • 5 Zahavi J, Betteridge JD, Jones NAG, Galton DJ, Kakkar VV. Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia. Am J Med 1981; 70: 59-64
    CrossrefPubMedGoogle Scholar
  • 6 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327
    CrossrefPubMedGoogle Scholar
  • 7 Bom GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
    PubMedGoogle Scholar
  • 8 Mehta P, Mehta J. Platelet function studies in coronary heart disease: VIII. Decreased platelet sensitivity to prostacyclin in patients with myocardial ischaemia. Thromb Res 1980; 18: 273-277
    CrossrefPubMedGoogle Scholar
  • 9 Lewy RJ, Smith JB, Silver MJ, Saia J, Walinski P, Weiner L. Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal angina. Prostaglandins Med 1979; 42: 425-431
    PubMedGoogle Scholar
  • 10 Roschlau P, Berut E, Gruber W. Enzymatische Bestimmung des Gesamt-Cholesterins in Serum. Z Klin Chem Klin Biochem 1974; 12: 226-231
    PubMedGoogle Scholar
  • 11 Wahlefeld AW, Bergmeyer HU. Methoden der enzymatischen Analyse. 3.. Band II, Verlag Chemie Weinheim: 1974: 1878-1886
    Google Scholar
  • 12 Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882-888
    PubMedGoogle Scholar
  • 13 Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugal separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353
    CrossrefPubMedGoogle Scholar
  • 14 Laurell S. Plasma free fatty acids in diabetic acidosis and starvation. Scand J Clin Invest 1956; 8: 81-82
    CrossrefPubMedGoogle Scholar
  • 15 Kannel WB, Castelli WB, McNamara PM. The coronary profile: 12 year follow-up in the Framingham study. J Occup Med 1967; 9: 611-619
    PubMedGoogle Scholar
  • 16 Kannel WB, Castelli WB, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971; 74: 1-12
    CrossrefPubMedGoogle Scholar
  • 17 Shattil SJ, Ahaya-Galindo R, Bennet J, Colman RW, Cooper RA. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 1975; 55: 115-126
    CrossrefPubMedGoogle Scholar
  • 18 Carvalho ACA, Lees RS. Platelets, intravascular coagulation and fibrinolysis in hyperlipidaemias: relationship to thromboembolic complications. Acta Med Scand (Suppl) 1980; 642: 101-112
    PubMedGoogle Scholar
  • 19 Wörner P, Patscheke H. Hyperreactivity by an enhancement of the arachidonate pathway of platelets treated with cholesterol-rich phospholipid-dispersions. Thromb Res 1980; 18: 439-451
    CrossrefPubMedGoogle Scholar